Nephrology

SLE

Questions discussed in this category

What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?

What key factors will you consider when selecting patients for this therapy?This question is part of a collaboration with RheumMadness and i...

1 Answer available

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab in Lupus Nephritis

2 Answers available

Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?

When do you decide to hospitalize?

1 Answer available

Would you feel comfortable adding benlysta to patient already taking both mycophenolate and tacrolimus (and hydroxychloroquine) who still has some evidence of active lupus nephritis?

3 Answers available

Is there a role for eculizumab in the management of refractory lupus nephritis?

3 Answers available

Papers discussed in this category

Arthritis and rheumatism, 2012-04

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Annals of the rheumatic diseases, 2021 Oct 06

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

The New England journal of medicine, 2025 Feb 07

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Rheumatology international, 2017 Mar 03

Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.

Rheumatology (Oxford, England), 2015 Aug 27

Eculizumab as rescue therapy in severe resistant lupus nephritis.

Arthritis and rheumatism, 2011-12

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

N Engl J Med,

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Lupus,

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.

Arthritis Rheumatol, 2017 Apr 07

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

Lancet (London, England), 2011 Feb 04

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Related Topics in Nephrology